Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America

Volumn 23, Issue 4, 2009, Pages 633-654

  Heerema McKenney, Amy ^a   Arber, Daniel A ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Myelodysplasia related changes; Recurrent genetic abnormalities; Therapy related myeloid neoplasms; WHO 2008 classification

Indexed keywords

ALKYLATING AGENT; CCAAT ENHANCER BINDING PROTEIN ALPHA; GYRASE INHIBITOR; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; CANCER CLASSIFICATION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 3; CHROMOSOME TRANSLOCATION 6; CHROMOSOME TRANSLOCATION 8; CHROMOSOME TRANSLOCATION 9; CYTOGENETICS; DIAGNOSTIC PROCEDURE; GENE MUTATION; HUMAN; LEUKEMOGENESIS; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVIEW; WORLD HEALTH ORGANIZATION;

ACUTE DISEASE; CHROMOSOME ABERRATIONS; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; PROGNOSIS; WORLD HEALTH ORGANIZATION;

EID: 67649447374     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.04.003     Document Type: Review

References (45)

1. Arber D.A., Brunning R.D., LeBeau M.M., et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition (2008), IARC Press, Lyon 110-123
2. Arber D.A., Brunning R.D., Orazi A., et al. Acute myeloid leukaemia, not otherwise specified. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition (2008), IARC Press, Lyon 130-139
3. Arber D.A., Brunning R.D., Orazi A., et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition (2008), IARC Press, Lyon 124-129
4. Vardiman J.W., Arber D.A., Brunning R.D., et al. Therapy-related myeloid neoplasms. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition (2008), IARC Press, Lyon 127-129
5. Baumann I., Niemeyer C.M., Brunning R.D., et al. Myeloid proliferations related to Down syndrome. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), IARC Press, Lyon 142-144
6. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program 2008 (2008) 1-11
7. Paschka P. Core binding factor acute myeloid leukemia. Semin Oncol 35 (2008) 410-417
8. Boissel N., Leroy H., Brethon B., et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20 (2006) 965-970
9. Goemans B.F., Zwaan C.M., Miller M., et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19 (2005) 1536-1542
10. Shimada A., Taki T., Kubota C., et al. N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t(8;21) in Japan: a study of the Japanese childhood AML cooperative study group. Leukemia 21 (2007) 2218-2219
11. Gale R.E., Hills R., Pizzey A.R., et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106 (2005) 3768-3776
12. Lo-Coco F., Ammatuna E., Montesinos P., et al. Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol 35 (2008) 401-409
13. Sainty D., Liso V., Cantu-Rajnoldi A., et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Group Francais de Cytogenetique Hematologique, UK Cancer Cytogenetics Group and BIOMED 1 European Coomunity-Concerted Acion Molecular Cytogenetic Diagnosis in Haematological Malignancies. Blood 96 (2000) 1287-1296
14. Lin P., Hao S., Medeiros L.J., et al. Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis. Am J Clin Pathol 121 (2004) 402-407
15. Chen W., Rassidakis G.Z., Li J., et al. High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). Blood 108 (2006) 1783-1784
16. Kussick S.J., Stirewalt D.L., Yi H.S., et al. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia 18 (2004) 1591-1598
17. Ito S., Ishida Y., Oyake T., et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma 45 (2004) 1783-1789
18. Meyer C., Schneider B., Jakob S., et al. The MLL recombinome of acute leukemias. Leukemia 20 (2006) 777-784
19. Shih L.Y., Liang D.C., Fu J.F., et al. Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia 20 (2006) 218-223
20. Meshinchi S., Alonzo T.A., Stirewalt D.L., et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 108 (2006) 3654-3661
21. Lugthart S., van Drunen E., van Norden Y., et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111 (2008) 4329-4337
22. Alsabeh R., Brynes R.K., Slovak M.L., et al. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol 107 (1997) 430-437
23. Chi Y., Lindgren V., Quigley S., et al. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med 132 (2008) 1835-1837
24. Slovak M.L., Gundacker H., Bloomfield C.D., et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 20 (2006) 1295-1297
25. Hasle H., Alonzo T.A., Auvrignon A., et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood 109 (2007) 4641-4647
26. Weisser M., Haferlach C., Haferlach T., et al. Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML. Leuk Lymphoma 48 (2007) 2145-2151
27. Bernstein J., Dastugue N., Haas O.A., et al. Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia 14 (2000) 216-218
28. Hama A., Yagasaki H., Takahashi Y., et al. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome. Br J Haematol 140 (2008) 552-561
29. Athale U.H., Kaste S.C., Razzouk B.I., et al. Skeletal manifestations of pediatric acute megakaryoblastic leukemia. J Pediatr Hematol Oncol 24 (2002) 561-565
30. Gilliland D.G. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 39 (2002) 6-11
31. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358 (2008) 1909-1918
32. Baldus C.D., Mrozek K., Marcucci G., et al. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br J Haematol 137 (2007) 387-400
33. Rausei-Mills V., Chang K.L., Gaal K.K., et al. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. Am J Clin Pathol 129 (2008) 624-629
34. Brown P., McIntyre E., Rau R., et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 110 (2007) 979-985
35. Falini B., Mecucci C., Saglio G., et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 93 (2008) 439-442
36. Ho P., Alonzo T.A., Gerbing R., et al. Prevalence and prognostic implications of CEBPA mutations in pediatric AML, 2009: a report from the Children's Oncology Group (2009), Children's Oncology Group, Seattle (WA)
37. Leroy H., Roumier C., Huyghe P., et al. CEBPA point mutations in hematological malignancies. Leukemia 19 (2005) 329-334
38. Liang D.C., Shih L.Y., Huang C.F., et al. CEBPalpha mutations in childhood acute myeloid leukemia. Leukemia 19 (2005) 410-414
39. Weinberg O.K., Seetharam M., Ren L., et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 113 9 (2009) 1906-1908
40. Raimondi S.C., Chang M.N., Ravindranath Y., et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 94 (1999) 3707-3716
41. Breems D.A., Van Putten W.L., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26 (2008) 4791-4797
42. Kantarjian H., O'Brien S., Cortes J., et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113 (2008) 1933-1952
43. Lahortiga I., Vazquez I., Agirre X., et al. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Genes Chromosomes Cancer 40 (2004) 179-189
44. Rund D., and Ben-Yehuda D. Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment. Hematology 9 (2004) 179-187
45. Rund D., Krichevsky S., Bar-Cohen S., et al. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 19 (2005) 1919-1928